Inogen (INGN) Reports Q2 Loss, Beats Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 08 2025
0mins
Should l Buy LUCD?
Source: NASDAQ.COM
Inogen's Quarterly Performance: Inogen (INGN) reported a quarterly loss of $0.15 per share, outperforming the Zacks Consensus Estimate of a loss of $0.22, and generated revenues of $92.28 million, exceeding expectations by 1.76%. The company has consistently surpassed earnings estimates over the past four quarters.
Market Outlook and Industry Context: Despite underperforming the market with a 31.3% decline in shares this year, Inogen holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. The Medical - Instruments industry is currently ranked in the bottom 41%, which may impact stock performance moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LUCD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LUCD
Wall Street analysts forecast LUCD stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.050
Low
3.00
Averages
4.05
High
8.25
Current: 1.050
Low
3.00
Averages
4.05
High
8.25
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Uber's Q1 Earnings Miss Estimates but Guidance Surpasses Expectations
- Earnings Performance: Uber reported Q1 revenue of $13.2 billion, missing the market expectation of $13.29 billion, with earnings per share at 13 cents, significantly below the expected 70 cents, indicating challenges in a complex macro environment.
- Net Income Decline: Due to the revaluation of equity investments, Uber's net income fell from $1.78 billion a year ago to $263 million, reflecting the pressure of market volatility on the company's profitability.
- Delivery Segment Growth: Uber's delivery segment achieved a 34% revenue growth to $5.07 billion, surpassing analyst expectations of $4.89 billion, demonstrating strong performance in Australia, Japan, and the UK.
- Optimistic Future Guidance: Uber expects total bookings for Q2 to range between $56.25 billion and $57.75 billion, exceeding the consensus estimate of $56.17 billion, indicating a positive outlook for future growth.
See More
Berkshire Hathaway Annual Meeting Highlights
- Record Cash Reserves: Berkshire Hathaway's cash pile reached a record $397.4 billion in Q1, indicating the company's strong financial flexibility even in a less-than-ideal investment environment, thus laying the groundwork for future investment opportunities.
- Insurance Business Recovery: The growth in operating earnings was partly attributed to a rebound in the insurance sector, highlighting that insurance remains a crucial pillar for Berkshire, enhancing its overall profitability amid economic fluctuations.
- Lackluster Shareholder Meeting: Although CEO Greg Abel performed well at the annual meeting, the turnout for the 'Berkshire Bazaar of Bargains' was noticeably lower than in previous years, reflecting waning investor interest without Warren Buffett at the helm.
- Cautious Market Outlook: Buffett noted that the current investment environment is not ideal, yet Abel's leadership style mirrors Buffett's, which may continue to attract investor confidence in the future.
See More
PAVmed to Host Business Update Conference Call
- Conference Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D. will outline the company's operations and growth strategy, aiming to bolster investor confidence in future developments.
- Financial Results: CFO Dennis McGrath will discuss PAVmed's first quarter 2026 financial results during the call, expected to provide key financial metrics to assess the company's market performance and financial health.
- Webcast Availability: The conference call will be available via webcast on the company's investor relations section, allowing investors to dial in through specified numbers, ensuring broad dissemination and transparency of information.
- Replay Accessibility: Following the call, a replay will be available for 30 days on the investor relations section of the company's website, facilitating access for investors who could not participate live, thereby enhancing communication efficiency between the company and its investors.
See More
PAVmed to Host Business Update Conference Call
- Conference Call Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and future growth potential.
- Webcast Availability: The webcast will be available on the investor relations section of the company's website, allowing global investors to participate in real-time and access the latest information, enhancing transparency and engagement.
- Replay Service: A replay of the call will be available for 30 days on the company's website, ensuring that investors who cannot attend live can still access important information, further improving communication efficiency between the company and its investors.
See More
Lucid Diagnostics to Host Business Update Conference Call
- Conference Details: Lucid Diagnostics will host a business update conference call on May 14, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D., will outline the company's operations and growth strategy, which is expected to positively influence investor sentiment.
- Financial Results: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and performance.
- Investor Relations: The webcast will be available on the company's investor relations section, enhancing transparency and providing investors with direct access to information, which is likely to boost investor confidence.
- Cancer Prevention Focus: Lucid Diagnostics is dedicated to cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices aimed at reducing cancer risk through early detection, aligning with the current healthcare industry's emphasis on early diagnosis.
See More
Lucid Diagnostics to Host Business Update Conference Call
- Conference Call Details: Lucid Diagnostics will host a business update conference call on May 14, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and performance.
- Investor Relations Access: The webcast will be available on the company's investor relations section, enhancing transparency and providing investors with convenient access to important information.
- Cancer Prevention Focus: Lucid Diagnostics is dedicated to cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices aimed at reducing cancer risk through early detection, aligning with the company's long-term social responsibility and market needs.
See More
Uber's Q1 Earnings Miss Estimates but Guidance Surpasses Expectations
- Earnings Performance: Uber reported Q1 revenue of $13.2 billion, missing the market expectation of $13.29 billion, with earnings per share at 13 cents, significantly below the expected 70 cents, indicating challenges in a complex macro environment.
- Net Income Decline: Due to the revaluation of equity investments, Uber's net income fell from $1.78 billion a year ago to $263 million, reflecting the pressure of market volatility on the company's profitability.
- Delivery Segment Growth: Uber's delivery segment achieved a 34% revenue growth to $5.07 billion, surpassing analyst expectations of $4.89 billion, demonstrating strong performance in Australia, Japan, and the UK.
- Optimistic Future Guidance: Uber expects total bookings for Q2 to range between $56.25 billion and $57.75 billion, exceeding the consensus estimate of $56.17 billion, indicating a positive outlook for future growth.
See More
Berkshire Hathaway Annual Meeting Highlights
- Record Cash Reserves: Berkshire Hathaway's cash pile reached a record $397.4 billion in Q1, indicating the company's strong financial flexibility even in a less-than-ideal investment environment, thus laying the groundwork for future investment opportunities.
- Insurance Business Recovery: The growth in operating earnings was partly attributed to a rebound in the insurance sector, highlighting that insurance remains a crucial pillar for Berkshire, enhancing its overall profitability amid economic fluctuations.
- Lackluster Shareholder Meeting: Although CEO Greg Abel performed well at the annual meeting, the turnout for the 'Berkshire Bazaar of Bargains' was noticeably lower than in previous years, reflecting waning investor interest without Warren Buffett at the helm.
- Cautious Market Outlook: Buffett noted that the current investment environment is not ideal, yet Abel's leadership style mirrors Buffett's, which may continue to attract investor confidence in the future.
See More
PAVmed to Host Business Update Conference Call
- Conference Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D. will outline the company's operations and growth strategy, aiming to bolster investor confidence in future developments.
- Financial Results: CFO Dennis McGrath will discuss PAVmed's first quarter 2026 financial results during the call, expected to provide key financial metrics to assess the company's market performance and financial health.
- Webcast Availability: The conference call will be available via webcast on the company's investor relations section, allowing investors to dial in through specified numbers, ensuring broad dissemination and transparency of information.
- Replay Accessibility: Following the call, a replay will be available for 30 days on the investor relations section of the company's website, facilitating access for investors who could not participate live, thereby enhancing communication efficiency between the company and its investors.
See More
PAVmed to Host Business Update Conference Call
- Conference Call Details: PAVmed will host a business update conference call on May 15, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and future growth potential.
- Webcast Availability: The webcast will be available on the investor relations section of the company's website, allowing global investors to participate in real-time and access the latest information, enhancing transparency and engagement.
- Replay Service: A replay of the call will be available for 30 days on the company's website, ensuring that investors who cannot attend live can still access important information, further improving communication efficiency between the company and its investors.
See More
Lucid Diagnostics to Host Business Update Conference Call
- Conference Details: Lucid Diagnostics will host a business update conference call on May 14, 2026, at 8:30 AM ET, where CEO Lishan Aklog, M.D., will outline the company's operations and growth strategy, which is expected to positively influence investor sentiment.
- Financial Results: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and performance.
- Investor Relations: The webcast will be available on the company's investor relations section, enhancing transparency and providing investors with direct access to information, which is likely to boost investor confidence.
- Cancer Prevention Focus: Lucid Diagnostics is dedicated to cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices aimed at reducing cancer risk through early detection, aligning with the current healthcare industry's emphasis on early diagnosis.
See More
Lucid Diagnostics to Host Business Update Conference Call
- Conference Call Details: Lucid Diagnostics will host a business update conference call on May 14, 2026, at 8:30 AM ET, where CEO Lishan Aklog will outline the company's operations and growth strategy, likely boosting investor confidence.
- Financial Results Discussion: CFO Dennis McGrath will discuss the first quarter 2026 financial results during the call, providing key financial metrics that will help investors assess the company's financial health and performance.
- Investor Relations Access: The webcast will be available on the company's investor relations section, enhancing transparency and providing investors with convenient access to important information.
- Cancer Prevention Focus: Lucid Diagnostics is dedicated to cancer prevention for patients with gastroesophageal reflux disease, with its EsoGuard® and EsoCheck® devices aimed at reducing cancer risk through early detection, aligning with the company's long-term social responsibility and market needs.
See More
